ArticleMaternal health, neonatology and perinatology2026
Factors associated with the uptake of intermittent preventive treatment of malaria in pregnancy in Nambale Sub-County Hospital, Kenya.
Article in Maternal health, neonatology and perinatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a significant public health problem globally, with highest morbidity and mortality reported in sub Saharan Africa. In 2022, 12.7 million (36%) Malaria in Pregnancy (MiP) cases in Sub Saharan Africa and 27% were reported from East Africa. In Kenya, 4,080,441 malaria cases and 5% MiP cases reported. Busia County, Kenya, reported 341,886 malaria cases and 22% MiP cases. WHO recommends administering intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) to prevent MIP in malaria-endemic zones. The objective of the study was to determine proportion of pregnant women utilizing IPTp-SP 3 and describe factors influencing utilization of IPTp-SP 3.
methodsA cross-sectional study was employed, pregnant women of nine months, aged 14-49 years were interviewed, using questionnaires on Kobo-collect. The dependent variable was the uptake of three doses of IPTp-SP, with sociodemographic, health facility and individual factors as the independent variables. Chi square test was used in bivariate analysis to determine association between independent variables and dependable variables, variable with p value of ≤ 0.2, were subjected to multivariable logistic regression analysis to identify significant factors (variables with p value of ≤ 0.05)
results384 pregnant women were interviewed, 90% resided in rural areas; 93% aware of IPTp use, 68% were married, 67% unemployed, 60% utilized IPTp-SP3 and 47% had secondary education. In the bivariate analysis, participant age 21-30 years {cOR = 2.34, 95% CI = 1.4-3.7}, belief in > 3 doses of IPTp preventing MiP {cOR = 3.09, 95% CI = 1.5-6.2}and having tertiary education {cOR = 2.71, 95% CI = 1.4-5.1} were associated with uptake of ≥3doses of IPTp. On multivariable logistics regression analysis, attendance of ANC at least 4 times {aOR = 8.42, 95% CI = 4.4-16.0} and uptake of IPTp-SP at 14-17 gestation weeks {aOR = 7.79, 95% CI = 3.2-18.7} independently associated with optimal utilization of IPTp (IPTp-SP3). CONCLUSION AND RECOMMENDATION: A sub-optimal IPTp-SP 3 utilization (60%) way below WHO target of 80%. ≥4ANC attendance and first IPTp-SP uptake at 14-17 gestation weeks were independently associated with optimal utilization of IPTp. Pregnant women attending ANC at the facility should ensure that they attend ANC at least four times and take at least three doses of IPTp for maximum protection against malaria in pregnancy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.